SCHEMBL3713429

SCHEMBL3713429

CNc1nc(Cl)nc2ccoc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.37
YTHDC1 Q96MU7 6/20 0.36
PDE2A O00408 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
APP P05067 2/20 0.35
PDE5A O76074 1/20 0.35
CYP1A2 P05177 3/20 0.33
CYP3A4 P08684 3/20 0.33
CYP2D6 P10635 2/20 0.33
MAPK1 P28482 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
HSD17B10 Q99714 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715489 0.81 SYK (0.41) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL3708672 0.81 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL3701517 0.79 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL3711032 0.78 ESR1 (0.45) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL3706397 0.78 LATS1 (0.36) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL3712627 0.77 APP (0.32) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL1709800 0.77 IRAK4 (0.49) YTHDC1CYP1A2CYP3A4CYP2D6MAPK1
SCHEMBL3706236 0.77 IRAK4 (0.35) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL7607941 0.76 KDM4E (0.35) ALDH1A1LMNAKDM4EMAPT
SCHEMBL190033 0.75 TDP1 (0.31) TDP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 XDH 233/4885YTHDC1 4559/4885PDE2A 1415/4885
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT XDH 404/4885YTHDC1 2851/4885PDE2A 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.